| bioavailability = 40%<ref name = kin>{{cite journal|last=Kean|first=WF|author2=Hart, L |author3=Buchanan, WW |title=Auranofin.|journal=British Journal of Rheumatology|date=May 1997|volume=36|issue=5|pages=560â€“72|doi=10.1093/rheumatology/36.5.560|pmid=9189058|url=http://rheumatology.oxfordjournals.org/content/36/5/560.full.pdf|format=PDF}}</ref><ref name = MSR>{{cite web|title=Ridaura (auranofin) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=13 March 2014|url=http://reference.medscape.com/drug/ridaura-auranofin-343186#showall}}</ref>
